Migvax-101
From Handwiki Short description: Vaccine candidate against COVID-19
| Vaccine description | |
|---|---|
| Target disease | SARS-CoV-2 |
| Type | vlp |
| Clinical data | |
| Routes of administration | Oral |
MigVax-101 is a COVID-19 vaccine candidate developed by Oravax Medical.[1][2][3]
References
- ↑ "Israeli oral COVID-19 vaccine en route to clinical trials". The Jerusalem Post. 11 June 2021. https://www.jpost.com/health-science/israeli-researchers-say-oral-covid-19-vaccine-works-as-booster-study-670679.
- ↑ "Israel to become first in world to test Oravax oral COVID-19 vaccine". The Jerusalem Post. 22 July 2021. https://www.jpost.com/health-science/israel-to-become-first-in-world-to-test-oral-covid-19-vaccine-674563.
- ↑ "Oramed Announces Oravax's Oral COVID-19 Vaccine Has Received South African Approval to Initiate Phase 1 Trial". Cision PR News Wire. 29 October 2021. https://www.prnewswire.com/news-releases/oramed-announces-oravaxs-oral-covid-19-vaccine-has-received-south-african-approval-to-initiate-phase-1-trial-301411568.html.
 |
Categories: [Clinical trials]
↧ Download as ZWI file | Last modified: 02/28/2024 00:44:53 | 11 views
☰ Source: https://handwiki.org/wiki/Medicine:MigVax-101 | License: CC BY-SA 3.0
✘
ZWI is not signed. [what is this?]
ZWI viewer
by the 
KSF
KSF